Pulmagen Therapeutics is a development stage pharmaceutical company progressing novel therapies to treat chronic respiratory diseases including asthma, severe asthma, and COPD.

** Pulmagen Therapeutics announces positive data for ADC3680, a once daily, oral CRTh2 antagonist in eosinophilic asthma patients **

ss1 ss9 ss10 ss4 ss11 ss6 ss2 ss8

Pulmagen intends to progress its programs through Phase II proof-of-concept clinical trials and identify strategic partners for later stage clinical development.

The company has active partnered respiratory drug development programs with AstraZeneca, Chiesi, Dr. Reddy's, Skyepharma and Teijin.

Pulmagen Partners